

## CORRECTION



# Correction to: Overexpression of the *HMGA2* gene in transgenic mice leads to the onset of pituitary adenomas

Monica Fedele, Sabrina Battista, Lawrence Kenyon, Gustavo Baldassarre, Vincenzo Fidanza, Andres J. P. Klein-Szanto, A. F. Parlow, Rosa Visone, Giovanna M. Pierantoni, Eric Outwater, Massimo Santoro, Carlo M. Croce and Alfredo Fusco


© The Author(s), under exclusive licence to Springer Nature Limited 2022

*Oncogene* (2023) 42:406; <https://doi.org/10.1038/s41388-022-02535-z>


Correction to: *Oncogene* <https://doi.org/10.1038/sj.onc.1205428>, published online 07 May 2002

In addition, the following Fig. S1 is provided as supplementary material in support of the results published in Fig. 1B.

Following the publication of this article, it was noted that an incorrect beta-actin PCR gel image was presented in Fig. 1c. The corrected figure is shown below. This change does not affect the results and conclusions of this paper.



**Fig. 1C** Analysis of the expression of the *HMGA2* transgene by RT-PCR. Lanes 1-6: RNA extracted from different tissues of a *HMGA2* transgenic mouse; lanes 7 and 8: RNA extracted from a pool of pituitary glands and a spleen of control mice. White space between lanes 7 and 8 delineates the boundary between not contiguous lanes of the same gel.



**Figure S1.** Genotype analysis by Southern blot for the detection of the CMV/*HMGA2* integrated transgene. DNA samples were from the *HMGA2* transgenic mouse line 2. Wt, wild-type mouse (lanes 1, 3, 5); Tg, transgenic mouse (lanes 2, 4, 6); C-, wild-type control (negative control, lane 7); C+, transgenic control (positive control, lane 8).